Svenska
Svenska
News
News
Upcoming events
Subscribe
About us
About us
AlzeCure Pharma in brief
Mission, vision & strategy
A word from the CEO
Organization
Management team
Board of directors
Founders
Scientific advisors
Collaborations and Partnership
History
Career
Open positions
Research & development
Research & development
Project portfolio
NeuroRestore
Alzstatin
Alzheimer’s disease
Depression
Painless
ACD440
TrkA-NAM
Pain
Erythromelalgia
Small molecules
Publications
The patients story
Governance
Governance
Corporate Governance Reports
General meeting
General meetings
Nomination Committee
Board of directors
Management team
Remuneration
Auditors
Articles of association
Investors
Investors
Rights issue 2026
AlzeCure Pharma on First North Premier Growth Market
Certified Adviser
Prospectuses
The share
Trading information
Dividend policy
Ownership structure
Insiders
Analyst Coverage
Financial reports
Reports in pdf-format
Financial calendar
Presentations and Interviews
Press releases
Media
Media
Press releases
Presentations and Interviews
Video gallery
Image bank
Board of directors
Management
Founders
Logotype
Financial calendar
Subscribe
Contact
Subscribe
Contact
Contact
Office
Investors
Media
Search for:
Search
Media
Press releases
Final outcome of AlzeCure’s rights issue
July 2, 2026
AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project
July 1, 2026
Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026
June 29, 2026
All press releases
Calendar
Interim report Q2, April–June 2026
August 26, 2026
Interim report Q3, July–September 2026
November 11, 2026
Interim report Q4, October–December 2026
February 23, 2027
All events
